GB2431583A - Combination therapy using transferrin fusion proteins comprising GLP-1 - Google Patents
Combination therapy using transferrin fusion proteins comprising GLP-1Info
- Publication number
- GB2431583A GB2431583A GB0703685A GB0703685A GB2431583A GB 2431583 A GB2431583 A GB 2431583A GB 0703685 A GB0703685 A GB 0703685A GB 0703685 A GB0703685 A GB 0703685A GB 2431583 A GB2431583 A GB 2431583A
- Authority
- GB
- United Kingdom
- Prior art keywords
- transferrin fusion
- combination therapy
- glp
- fusion proteins
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 3
- 108090000901 Transferrin Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 239000012581 transferrin Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000003729 Neprilysin Human genes 0.000 abstract 2
- 108090000028 Neprilysin Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Abstract
The present invention provides combination therapy comprising transferrin fusion protein and DPP-IV inhibitors and/or neutral endopeptidase (NEP) inhibitors. The transferrin fusion protein comprises therapeutic polypeptides or peptides useful in the treatment of diseases such as diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59803104P | 2004-08-03 | 2004-08-03 | |
PCT/US2005/027800 WO2006017688A2 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0703685D0 GB0703685D0 (en) | 2007-04-04 |
GB2431583A true GB2431583A (en) | 2007-05-02 |
Family
ID=35839920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0703685A Withdrawn GB2431583A (en) | 2004-08-03 | 2007-02-26 | Combination therapy using transferrin fusion proteins comprising GLP-1 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1814599A4 (en) |
JP (1) | JP2008509153A (en) |
KR (1) | KR20070085224A (en) |
CN (1) | CN101035568A (en) |
AP (1) | AP2007003920A0 (en) |
AU (1) | AU2005271403A1 (en) |
BR (1) | BRPI0514115A (en) |
CA (1) | CA2575756A1 (en) |
CR (1) | CR8954A (en) |
EA (1) | EA200700391A1 (en) |
GB (1) | GB2431583A (en) |
IL (1) | IL181108A0 (en) |
MA (1) | MA28843B1 (en) |
MX (1) | MX2007001424A (en) |
NO (1) | NO20071018L (en) |
RU (1) | RU2007107808A (en) |
TN (1) | TNSN07039A1 (en) |
WO (1) | WO2006017688A2 (en) |
ZA (1) | ZA200701484B (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
PL1786784T3 (en) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Catalysis of diketopiperazine synthesis |
EP2322180B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Diketopiperazine salts for drug delivery |
WO2006096515A2 (en) * | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
RU2390325C2 (en) | 2005-09-14 | 2010-05-27 | Маннкайнд Корпорейшн | Method for preparing drug based on higher affinity of active agents to crystalline microparticle surfaces |
RU2403059C2 (en) | 2006-02-22 | 2010-11-10 | Маннкайнд Корпорейшн | Method of improving pharmaceutical properties of particles, containing diketopiperazine and active agent |
AU2007227202B2 (en) * | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
AU2007278994B2 (en) * | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US8636001B2 (en) | 2008-06-13 | 2014-01-28 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
DK2609954T3 (en) | 2008-06-20 | 2022-02-14 | Mannkind Corp | Interactive device for real-time imaging of inhalation performance |
TWI614024B (en) | 2008-08-11 | 2018-02-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
CN102647979B (en) | 2009-06-12 | 2015-03-04 | 曼金德公司 | Diketopiperazine particles with defined specific surface areas |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
EP2582421A1 (en) | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
US20130236911A1 (en) | 2010-08-27 | 2013-09-12 | University Of Miyazaki | Hemokinin-1 receptor and hemokinin-1-derived peptide |
WO2012135765A2 (en) | 2011-04-01 | 2012-10-04 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
RU2477726C1 (en) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
CN103945859A (en) | 2011-10-24 | 2014-07-23 | 曼金德公司 | Methods and compositions for treating pain |
CN103160565A (en) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Research for influence on endocytosis of cell transferrins of UNC-51 kinase |
CA2871468C (en) * | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
SG11201503526UA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
SG11201507564PA (en) | 2013-03-15 | 2015-10-29 | Mannkind Corp | Microcrystalline diketopiperazine compositions and methods |
CN103275177B (en) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application |
MX2020009878A (en) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Heat-stable dry powder pharmaceutical compositions and methods. |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
CN104645317B (en) * | 2015-01-28 | 2020-04-17 | 中国科学院天津工业生物技术研究所 | Application of polypeptide compound as polypeptide or protein drug carrier, method and fusion protein compound thereof |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
WO2018079702A1 (en) | 2016-10-28 | 2018-05-03 | 株式会社Nrlファーマ | Lactoferrin/albumin fusion protein and production method therefor |
WO2019014552A1 (en) * | 2017-07-14 | 2019-01-17 | University Of Southern California | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
ES2929416T3 (en) | 2018-06-21 | 2022-11-29 | Novo Nordisk As | New compounds for the treatment of obesity |
CN110218259B (en) * | 2019-06-24 | 2022-09-16 | 王跃驹 | Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules |
CN112661862B (en) * | 2020-12-25 | 2023-03-31 | 深圳大学 | Fusion protein and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US20020156036A1 (en) * | 2000-09-06 | 2002-10-24 | Nicolau Yves Claude | Methods and compositions for diseases associated with amyloidosis |
US20030138404A1 (en) * | 1995-07-14 | 2003-07-24 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US20030221201A1 (en) * | 2001-08-30 | 2003-11-27 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
JP2005513165A (en) * | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | Methods and compositions for the treatment of diabetes, hypertension, chronic heart failure and fluid retention |
DE60333306D1 (en) * | 2002-08-30 | 2010-08-19 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRIN FUSION PROTEINS WITH DOUBLE TRANSFERRIN AMINO OR CARBOXY TERMINALS DOMAINS |
-
2005
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/en active Application Filing
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/en unknown
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
- 2005-08-03 CA CA002575756A patent/CA2575756A1/en not_active Abandoned
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/en not_active IP Right Cessation
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/en unknown
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/en active Pending
- 2005-08-03 EP EP05782173A patent/EP1814599A4/en not_active Withdrawn
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/en not_active Withdrawn
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/en not_active Application Discontinuation
- 2005-08-03 EA EA200700391A patent/EA200700391A1/en unknown
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/en not_active Application Discontinuation
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/en not_active Application Discontinuation
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/en unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/en not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 CR CR8954A patent/CR8954A/en not_active Application Discontinuation
- 2007-03-02 MA MA29727A patent/MA28843B1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138404A1 (en) * | 1995-07-14 | 2003-07-24 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US20020156036A1 (en) * | 2000-09-06 | 2002-10-24 | Nicolau Yves Claude | Methods and compositions for diseases associated with amyloidosis |
US20030221201A1 (en) * | 2001-08-30 | 2003-11-27 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
Also Published As
Publication number | Publication date |
---|---|
WO2006017688A3 (en) | 2006-08-03 |
EP1814599A4 (en) | 2008-12-17 |
JP2008509153A (en) | 2008-03-27 |
EP1814599A2 (en) | 2007-08-08 |
IL181108A0 (en) | 2007-07-04 |
ZA200701484B (en) | 2008-07-30 |
CN101035568A (en) | 2007-09-12 |
MA28843B1 (en) | 2007-09-03 |
AU2005271403A1 (en) | 2006-02-16 |
KR20070085224A (en) | 2007-08-27 |
CR8954A (en) | 2007-10-02 |
RU2007107808A (en) | 2008-09-10 |
EA200700391A1 (en) | 2007-10-26 |
MX2007001424A (en) | 2008-03-13 |
CA2575756A1 (en) | 2006-02-16 |
GB0703685D0 (en) | 2007-04-04 |
NO20071018L (en) | 2007-04-11 |
WO2006017688A2 (en) | 2006-02-16 |
AP2007003920A0 (en) | 2007-02-28 |
BRPI0514115A (en) | 2008-05-27 |
TNSN07039A1 (en) | 2008-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2431583A (en) | Combination therapy using transferrin fusion proteins comprising GLP-1 | |
GEP20105111B (en) | Rage fusion proteins and methods of use | |
WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
WO2005067601A3 (en) | Vectors for recombinant protein expression in e.coli | |
DK1171465T3 (en) | Analogues to gastroinhibitory peptide and their use in the treatment of diabetes | |
WO2003103589A3 (en) | Use of il-21 in cancer and other therapeutic applications | |
DK1368060T3 (en) | HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease | |
DK1692158T3 (en) | VEGF binding and supported peptides for the treatment of skin diseases | |
DE69531889D1 (en) | Biologically active fragments of the glucagon-like, insulinotropic peptide | |
MX2007003907A (en) | Therapeutic agents with decreased toxicity. | |
AU2003228962A1 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
MX2009013372A (en) | Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury. | |
WO2007064917A3 (en) | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins | |
IL177049A (en) | HETERODIMERIC FOLLICLE STIMULATING HORMONE - Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY | |
IL176967A0 (en) | Il-4/il-13 specific polypetides and therapeutic uses thereof | |
EA200500218A1 (en) | TREATMENT OF KIDNEY INSUFFICIENCY WITH THE USE OF INTERFERON-β | |
UA107180C2 (en) | Rv1753c tuberculosis protein, composition containing it and administration | |
SG160205A1 (en) | Modified polypeptide | |
MXPA05008704A (en) | Fusion proteins of interferon alpha muteins with improved properties. | |
WO2005059131A3 (en) | Protein binding miniature proteins and uses thereof | |
WO2007018879A3 (en) | Interferon-gamma antagonists and therapeutic uses thereof | |
DE602004007924D1 (en) | THROMBOPOIETINE PROTEINS WITH IMPROVED PROPERTIES | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2006138610A3 (en) | Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof | |
DK1354054T3 (en) | Polypeptides capable of binding to CD64, comprising one or more heterologous T-cell epitopes, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1100120 Country of ref document: HK |
|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1100120 Country of ref document: HK |